CD19 and acute lymphoblastic leukemia: The use of second generation anti-CD19 CAR T cells have demonstrated high antitumor efficacy in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin lymphoma (NHL).